Protect your patients from exacerbations

Exacerbation protection demonstrated in Trial 2 (53% reduction vs placebo; NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001).1

Hear from a respiratory expert

Allergist Shahnaz Fatteh discusses treating severe eosinophilic asthma patients with frequent exacerbations and comorbid nasal polyps.

Exacerbation rate in severe eosinophilic asthma patients by atopic status

Trial 2/MUSCA Post-hoc meta-analysis: subgroup analysis4

Atopic status chart
Atopic status chart

Results are descriptive.

Of the total population (n=936), 907 patients had analyzable data.4


Positive atopic status defined as a RAST score ≥3 (ie, High or Very High allergic response) on at least 1 of 5 allergens: house dust mite, dog dander, cat dander, Alternaria, and cockroach.4

RAST=radioallergosorbent test.

Trial 2/MUSCA post hoc meta-analysis study design2 evaluated annual rate of exacerbations in select subgroups of patients with severe eosinophilic asthma.